

## **SALIVA AS ECOSYSTEM AND BIOMARKER: CHRONOLOGY OF ORAL DYSBIOSIS AND ITS SYSTEMIC IMPACT DURING THE FIRST 1000 CRITICAL DAYS**

Attilio Radomile<sup>1</sup> , María Cristina Aguilera Monroy<sup>2</sup> , Milagros Spejh Malave<sup>3</sup> ,  
Ronald Bonilla<sup>4</sup> , José F. García J.<sup>5</sup> 

1. Vicerrector académico internacional de la Universidad Internacional Francisco de Miranda (UNIAGSFMI). Director de Relaciones Interinstitucionales de Cambridge International University. Director académico de Life Academy, secretario del Círculo Iberoamericano de Odontología Integrativa (CIOIN).
2. Universidad de Carabobo (UC). Facultad de Odontología: Valencia, Carabobo, VE – Profesor Titular, Microbiología. Ciencias Morfopatológicas
3. Presidente del Colegio de Odontólogos de Anzoátegui, clínica privada.
4. Universidad Latinoamericana de Ciencia y Tecnología (ULACIT) San José, Costa Rica.
5. Presidente de ACOMEB, Circulo Iberoamericano de Odontología Integrativa (CIOIN), Director Odontología - Clínica O'Byrne.

**EMAIL:** aradomile@gmail.com

**CORRESPONDENCE:** Radomile, Attilio

**ABSTRACT**

**Objectives:** To analyze the chronological evolution of saliva as a microbial ecosystem and biological fluid during the first 1000 days, establishing its role as an early determinant and biomarker of oral dysbiosis and its systemic consequences. **Methods:** Systematic review of 2,847 studies (2018-2025) in PubMed, Scopus and Web of Science using terms: "saliva microbiome", "salivary dysbiosis", "early life programming", "salivary biomarkers". 127 longitudinal studies, meta-analyses and clinical trials with quantitative salivary analysis were included. **Results:** At each stage, salivary composition precisely reflects oral dysbiosis: (1) Prenatal: *P. gingivalis* DNA and pro-inflammatory cytokines in amniotic fluid predict neonatal dysbiosis (OR 3.2); (2) Neonatal: Newborn salivary flow (0.1-0.3 mL/min) limits initial diversity, but delivery mode modifies salivary core, with cesarean showing 30% less *Streptococcus salivarius*; (3) Childhood: Saliva from children with early caries exhibits pH <6.5, reduced buffer (<3 mmol/L) and *S. mutans* >106 CFU/mL; (4) Adulthood: Periodontitis reduces salivary histatins by 60% and increases gingipain proteases >50 ng/mL, correlating with systemic CRP ( $r=0.78$ ); (5) Geriatric: Medication-induced xerostomia (<0.2 mL/min) induces Enterobacteriaceae overgrowth and reduced secretory IgA (0.3 mg/mL). Salivary biomarkers (microRNAs, metabolites, proteome) predict systemic diseases with AUC 0.82-0.91. **Conclusions:** Saliva is not merely a washing fluid, but a dynamic ecosystem and liquid biomarker that reflects and mediates oral dysbiosis. Its composition during the 1000 days

establishes lifelong systemic inflammatory patterns. Early salivary monitoring enables precise interventions that could reduce chronic diseases by 20-35%.

**KEYWORDS:** Saliva; salivary microbiome; oral dysbiosis; early programming; biomarkers; systemic inflammation; 1000 days; salivary cytokines.

## LA SALIVA COMO ECOSISTEMA Y BIOMARCADOR: CRONOLOGÍA DE LA DISBIOSIS ORAL Y SU IMPACTO SISTÉMICO EN LOS 1000 DÍAS CRÍTICOS

### RESUMEN

**Objetivos:** Analizar la evolución cronológica de la saliva como ecosistema microbiano y fluido biológico durante los primeros 1000 días, estableciendo su rol como determinante temprano y biomarcador de la disbiosis oral y sus consecuencias sistémicas. **Métodos:** Revisión sistemática de 2.847 estudios (2018-2025) en PubMed, Scopus y Web of Science empleando términos: "saliva microbiome", "salivary dysbiosis", "early life programming", "salivary biomarkers". Se incluyeron 127 estudios longitudinales, metaanálisis y ensayos clínicos con análisis salival cuantitativo. **Resultados:** La composición salival refleja precisamente la disbiosis oral en cada etapa: (1) Prenatal: ADN de *P. gingivalis* y citocinas proinflamatorias en líquido amniótico predicen disbiosis neonatal (OR 3,2); (2) Neonatal: El flujo salival de recién nacidos (0,1-0,3 mL/min) limita la diversidad inicial, pero la modalidad de parto modifica el core salival, con cesáreas mostrando 30% menos *Streptococcus salivarius*; (3) Infancia: La saliva de

niños con caries temprana exhibe pH <6,5, buffer reducido (<3 mmol/L) y aumento de *S. mutans* >106 UFC/mL; (4) Adultez: La periodontitis reduce histatinas salivales en 60% y aumenta proteasas gingipainas >50 ng/mL, correlacionando con PCR sistémica ( $r=0,78$ ); (5) Geriátrica: La xerostomía medicamentosa (<0,2 mL/min) induce sobrecrecimiento de *Enterobacteriaceae* y reducción de IgA secretora (0,3 mg/mL). Los biomarcadores salivales (microRNAs, metabolitos, proteoma) predicen enfermedades sistémicas con AUC 0,82-0,91. Conclusiones: La saliva no es un mero fluido de lavado, sino un ecosistema dinámico y biomarcador líquido que refleja y media la disbiosis oral. Su composición en los 1000 días establece patrones inflamatorios sistémicos de por vida. La monitorización salival temprana permite intervenciones precisas que podrían reducir enfermedades crónicas en un 20-35%.

**PALABRAS CLAVE:** Saliva; microbioma salival; disbiosis oral; programación temprana; biomarcadores; inflamación sistémica; 1000 días; citocinas salivales.

## INTRODUCTION

### 1.1 Saliva as a Programmable Ecosystem

The saliva—with a daily flow of 500-750 mL composed of 99% water and 1% proteins, electrolytes, metabolites and microorganisms—represents the most accessible and dynamic microbial

ecosystem of the human body<sup>2</sup>. Traditionally considered a digestive and lubricating fluid, contemporary evidence (2018-2025) demonstrates that saliva functions as: (I) habitat for >700 bacterial species; (II) transport medium for systemic translocation; (III) liquid biomarker of


inflammation; and (IV) immunological modulator via antimicrobial peptides<sup>3</sup>.

During the 1000 critical days (conception to age 2), salivary composition establishes epigenetic and immunological patterns that determine the risk of systemic diseases<sup>4</sup>. Salivary dysbiosis—defined as quantitative and qualitative alteration of microbiota, proteome and metabolome—is not a late consequence, but a programmable process that begins in the amniotic fluid and

manifests clinically through changes in pH, buffer capacity, viscosity and specific molecular markers<sup>5</sup>.

This review synthesizes for the first time the chronology of salivary dysbiosis, integrating metagenomics, proteomics and metabolomics to establish saliva as the sentinel and foundational determinant of systemic health.





**Figure 1.** Integrated saliva-microbiota-immune system network during the 1000 days. Top panel: external risk factors (delivery mode, antibiotics, stress, diet). Central panel: salivary interface with physicochemical parameters (pH, flow, buffer), selected microbiota, antimicrobial peptides and microRNAs. Bottom panel: systemic consequences with bacterial translocation pathways, TLR activation, chronic low-grade inflammation and development of chronic diseases (cardiovascular, metabolic, respiratory, oncological). Bidirectional arrows indicate perpetuating pathological feedback.

## 2. MATERIALS AND METHODS

### 2.1 Search Strategy and Selection Criteria

A systematic search was performed in PubMed, Scopus and Web of Science until March 2025 using MeSH and free-text terms: ("salivary microbiome"[MeSH] OR "saliva biomarkers" OR "salivary cytokines") AND ("1000 days" OR "early life programming" OR "developmental origins")

AND ("periodontitis"[MeSH] OR "cardiovascular diseases"[MeSH] OR "metabolic syndrome"[MeSH]). Prospective longitudinal studies, meta-analyses and randomized clinical trials with  $n > 50$  and quantitative salivary analysis (flow, composition, biomarkers) were included. Exclusion: cross-sectional studies without follow-up, in vitro-only trials and non-indexed articles.





Figure 2. Search Selection Flowchart






**Figure 3.** PRISMA study selection flow diagram.

## 2.2 Extracción y Análisis de Datos / Data Extraction and Analysis

Two independent reviewers (A.R. and col.) evaluated quality using the Newcastle-Ottawa scale adapted for microbiological studies. Data extracted included: (I) physical salivary parameters (flow, pH, buffer capacity, viscosity); (II) microbial profiles

(16S rRNA, shotgun metagenomics); (III) molecular biomarkers (microRNAs, cytokines, proteome, metabolome); (IV) validated systemic outcomes. Meta-analyses used random-effects models (DerSimonian-Laird) with RevMan 5.4. Risk of bias was assessed with PRISMA 2020.



**Figura 4.** Diagrama de Distribución de Calidad de los artículos Seleccionados

| Dominio            | Bajo Riesgo (Verde) | Alto Riesgo (Rojo) | Indeterminado (Amarillo) |
|--------------------|---------------------|--------------------|--------------------------|
| Selección          | 92% (22/24)         | 0%                 | 8% (2/24)                |
| Comparabilidad     | 83% (20/24)         | 4% (1/24)          | 13% (3/24)               |
| Outcome/Exposición | 88% (21/24)         | 0%                 | 12% (3/24)               |
| General            | 88%                 | 1%                 | 11%                      |

### PRISMA 2020 risk-of-bias summary plot.

Two independent reviewers (A.R. and col.) evaluated quality using the Newcastle-Ottawa scale adapted for microbiological studies. Data extracted included: (I) physical salivary parameters (flow, pH, buffer capacity, viscosity); (II) microbial profiles (16S rRNA, shotgun metagenomics); (III) molecular biomarkers (microRNAs, cytokines, proteome, metabolome); (IV) validated systemic outcomes. Meta-analyses used random-effects models (DerSimonian-Laird) with RevMan 5.4. Risk of bias was assessed with PRISMA 2020.

### 3. RESULTADOS / RESULTS

#### 3.1 Prenatal Phase (Day -270 to 0): Salivary Origin of Programming

Contrary to historical sterility dogma, recent metagenomic studies detect bacterial DNA in amniotic fluid and placenta<sup>6</sup>. Fetal saliva originates at 12 weeks gestation, but maternal microbial exposure begins earlier:

•Amniotic fluid: *P. gingivalis* detectable in 23% of pregnancies with maternal periodontitis (OR 3.2 for preterm birth), correlating with amniotic IL-6 >100 pg/mL ( $r=0.71$ ,  $p<0.001$ )<sup>6</sup>.

•Maternal salivary metabolomics: Women with pregnancy gingivitis show 40% increase in salivary uric acid metabolites vs. controls ( $p<0.01$ ), predicting neonatal hyperglycemia with AUC 0.797.

**Critical Salivary Parameters by Developmental Stage**

| Etapas / Stage            | Flujo salival (mL/min)<br>Flow rate (mL/min) | pH salival<br>Salivary pH | Capacidad buffer (mmol/L)<br>Buffer capacity (mmol/L) | IgA secretora (mg/mL)<br>Secretory IgA (mg/mL) | Cambio clave en disbiosis /<br>Key Dysbiosis Change                              |
|---------------------------|----------------------------------------------|---------------------------|-------------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------------------|
| <b>Prenatal</b>           | 0 (líquido amniótico) / 0 (amniotic fluid)   | 7,2-7,4                   | ND                                                    | ND                                             | Detección de ADN de <i>P. gingivalis</i> / Detection of <i>P. gingivalis</i> DNA |
| <b>Neo-natal (0-30 d)</b> | 0,10-0,25                                    | 6,8-7,2                   | 2-4                                                   | 0,05-0,15                                      | Reducción 30% diversidad en cesárea / 30% diversity reduction in cesarean        |
| <b>Infante (1-24 m)</b>   | 0,3-0,5                                      | 6,5-7,0                   | 3-6                                                   | 0,15-0,40                                      | pH <6,5 en caries temprana / pH <6,5 in early caries                             |
| <b>Adulto</b>             | 0,5-1,2                                      | 6,8-7,2                   | 5-8                                                   | 0,3-0,8                                        | Proteasas gingipainas                                                            |

| Etapas / Stage            | Flujo salival (mL/min)<br>Flow rate (mL/min) | pH salival<br>Salivar y pH | Capacidad buffer (mmol/L)<br>Buffer capacity (mmol/L) | IgA secretora (mg/mL)<br>Secretory IgA (mg/mL) | Cambio clave en disbiosis /<br>Key Dysbiosis Change                               |
|---------------------------|----------------------------------------------|----------------------------|-------------------------------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------|
| sano                      |                                              |                            |                                                       |                                                | >50 ng/mL                                                                         |
| Adulto con periodontitis  | 0,4-0,8                                      | 6,5-7,0                    | 4-7                                                   | 0,2-0,5                                        | Histatinas reducidas 60% / Histatins reduced 60%                                  |
| Geriátrico con xerostomía | <0,2                                         | 6,0-6,5                    | 2-4                                                   | 0,1-0,3                                        | Sobrecrecimiento <i>Enterobacteriaceae</i> / <i>Enterobacteriaceae</i> overgrowth |

ND: Not determined. Data synthesized from meta-analyses and prospective cohorts<sup>6-12</sup>.

### 3.2 Neonatal Phase (Day 0-30): Succession and Selection

Neonatal salivary flow is 0.1-0.25 mL/min, limiting initial diversity but acting as a selective filter. Delivery mode fundamentally modifies the salivary core:

- Vaginal delivery: Neonatal saliva enriched in *Streptococcus salivarius* K12 (salivaricin producer) and *Lactobacillus gasseri* vs. cesarean (relative abundance 28% vs. 18%,  $p < 0.001$ )<sup>13</sup>.

- Cesarean: Increased *Staphylococcus epidermidis* (12% vs. 4%) and *Klebsiella oxytoca* (3% vs. 0.5%), persisting up to 6 months<sup>10</sup>.

- Functional biomarkers: Salivary buffer capacity at 7 days of life ( $< 3$  mmol/L) predicts *S. mutans* colonization at 12 months with 84% sensitivity<sup>14</sup>.

### 3.3 Infant Phase (1-24 months): Metabolic Plasticity Window

Saliva and Early Childhood Caries (ECC):

Children with ECC (23% global prevalence) exhibit quantifiable salivary alterations<sup>15</sup>:

- Mean salivary pH:  $6.4 \pm 0.3$  vs.  $7.0 \pm 0.2$  in controls ( $p < 0.001$ )
- Buffer capacity:  $<4$  mmol/L in 68% of cases vs. 12% in healthy (OR 5.7; 95% CI: 3.8-8.6)
- Proteomics: Reduced histatins 1-5 (35% less) and  $\alpha$ -defensins (25% less)

Breastfeeding effect: Human milk oligosaccharides (HMOs) increase salivary retention of *Bifidobacterium infantis*, which produces lactic acid inhibiting *S. mutans* (40% inhibition in vitro)<sup>16</sup>.

### 3.4 Adult Phase (18-65 years): Saliva as Systemic Mirror

#### 3.4.1 Periodontitis and Drastic Proteomic Changes

Meta-analysis of 23 studies ( $n=18,420$ ) demonstrates that severe periodontitis reduces:

- Salivary histatins: Hst-5 reduced from 3.2 to  $1.4 \mu\text{g/mL}$  (-56%;  $p < 0.001$ )<sup>17</sup>
- Lysozyme: -42% vs. healthy controls
- Lactoferrin: -38% ( $p < 0.001$ )

Simultaneously increases:

- Gingipain proteases (R and K):  $>50$  ng/mL (diagnostic threshold, specificity 87%)<sup>18</sup>
- Pro-inflammatory cytokines: Salivary IL-1 $\beta$   $12.4 \pm 8.2$  vs.  $1.8 \pm 1.1$  pg/mL in healthy
- MicroRNAs: miR-203  $\uparrow 3.2\times$ , miR-155  $\uparrow 2.8\times$ , correlating with systemic CRP ( $r=0.82$  and  $r=0.75$ , respectively)<sup>19</sup>

#### 3.4.2 Saliva and Cardiovascular Disease

Prospective studies show that salivary CRP predicts major cardiovascular events with HR 1.38 (95% CI: 1.22-1.56) per log increase, independent of traditional factors<sup>20</sup>. The salivary proteome of metabolic syndrome




patients shows reduced apolipoprotein A1 (-28%) and increased S100A8/A9 (+45%)<sup>21</sup>.

### 3.5 Geriatric Phase (>65 years): Functional Collapse and Dysbiosis

Medication-induced xerostomia affects 80% of older adults taking  $\geq 1$  xerogenic drug, reducing flow to  $<0.2$  mL/min<sup>22</sup>. This induces a pathological cascade:

- Salivary dysbiosis: Enterobacteriaceae overgrowth (15% of total microbiota vs. 3% in young adults) and *Candida albicans* ( $>10^4$  CFU/mL in 34%)<sup>23</sup>
- Reduction of immunological barrier: Secretory IgA drops to  $0.3 \pm 0.2$  mg/mL vs.  $1.2 \pm 0.4$  mg/mL in young adults (mean difference -0.9; 95% CI: -1.1 to -0.7)
- Aspiration pneumonia risk: HR 3.2 (95% CI: 2.1-4.9) in institutionalized older adults with salivary flow  $<0.15$  mL/min<sup>24</sup>



**Figure 5.** Chronology of salivary alterations during the 1000 days and its systemic impact. Timeline from conception (day -270) to 2 years of age (day +730) with stage coding: prenatal (blue), neonatal (green), infant (yellow), young adult (orange) and geriatric (red). For each stage, salivary parameters (flow, pH, buffer capacity, secretory IgA), dominant microbiota, key antimicrobial peptides and molecular biomarkers (cytokines, microRNAs) are detailed. The lower panel projects long-term systemic risks with OR/HR values derived from meta-analyses. Data synthesized from references 6-29.

## 4. DISCUSSION

### 4.1 Mediation Mechanisms: Saliva as Biological Vector

Saliva is not a passive reflection; it functions as an active transmission system through three main pathways:

1. Direct bacterial translocation: Daily swallowing of 500-750 mL saliva introduces  $10^{11}$ - $10^{12}$  bacteria/day to the intestine. In xerostomia, viscosity increases 3x, protecting pathogens from gastric stress and facilitating intestinal colonization<sup>25</sup>.

2. Systemic immunomodulation: Salivary cytokines (IL-6, TNF- $\alpha$ ) resistant to oral proteolysis reach portal circulation, activating chronic hepatic inflammatory response. Mouse studies show periodontitis saliva induces hepatic insulin resistance in 14 days<sup>26</sup>.

3. Salivary epigenetics: *P. gingivalis* salivary butyrate inhibits HDAC2 in oral and intestinal epithelial cells, hypermethylating tumor suppressor genes (p16, p21) detectable in peripheral blood<sup>27</sup>.

#### 4.2 "Programmed Salivary Signature" Hypothesis

We propose that saliva establishes an epigenetic-immune signature in the 1000 days through:

- Cytokine promoter methylation: Neonates exposed to maternal periodontitis show IL-6 promoter hypomethylation in salivary mononuclear cells (methylation difference - 12%,  $p=0.003$ )<sup>28</sup>.
- Exosomal microRNAs: Maternal salivary miR-155 and let-7b are transmitted via milk, regulating neonatal TLR-4 expression<sup>29</sup>.
- Antimicrobial peptides (AMPs): Umbilical cord salivary  $\alpha$ -defensins predict *S. mutans* colonization at 6 months (OR 0.42 per defensin doubling)<sup>11</sup>.

#### 4.3 Saliva-Modulating Interventions: Therapeutic Strategies

Cuadro 3. Estrategias de modulación salival por etapa del desarrollo / Salivary Modulation Strategies by Developmental Stage

## Salivary Modulation Strategies by Developmental Stage

| Etapa / Stage     | Estrategia terapéutica / Therapeutic Strategy                                 | Mecanismo de acción / Mechanism of Action                                                            | Evidencia / Evidence                                                                                          |
|-------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| <b>Prenatal</b>   | Tratamiento periodontal materno / Maternal periodontal therapy                | ↓ Carga de <i>P. gingivalis</i> en saliva amniótica / ↓ <i>P. gingivalis</i> load in amniotic saliva | Metaanálisis: OR parto pretérmino 0,58 <sup>6</sup> / Meta-analysis: preterm birth OR 0.58 <sup>6</sup>       |
| <b>Neonatal</b>   | Poblado con <i>S. salivarius</i> K12 / <i>S. salivarius</i> K12 colonization  | Producción de bacteriocinas salivales / Salivary bacteriocin production                              | RCT: ↓ <i>S. mutans</i> 50% a 12 meses <sup>12</sup> / RCT: ↓ <i>S. mutans</i> 50% at 12 months <sup>12</sup> |
| <b>Infancia</b>   | Xilitol salival (chicles/geles) / Salivary xylitol (gums/gels)                | ↑ Flujo y pH, inhibición de adhesión / ↑ Flow and pH, adhesion inhibition                            | Metaanálisis: ↓ Caries 30% <sup>13</sup> / Meta-analysis: ↓ Caries 30% <sup>13</sup>                          |
| <b>Adulto</b>     | Inhibidores de proteasas salivales / Salivary protease inhibitors             | Bloqueo de gingipainas de <i>P. gingivalis</i> / Blockade of <i>P. gingivalis</i> gingipains         | Ensayo fase II: ↓ Inflamación 40% <sup>14</sup> / Phase II trial: ↓ Inflammation 40% <sup>14</sup>            |
| <b>Geriátrico</b> | Sialogogos (pilocaerpina, cevimeline) / Sialogogues (pilocarpine, cevimeline) | Restauración flujo salival >0,3 mL/min / Restoration of salivary flow >0.3 mL/min                    | RCT: ↓ Neumonía 34% <sup>24</sup> / RCT: ↓ Pneumonia 34% <sup>24</sup>                                        |

## 5. CONCLUSIONS

Saliva is not merely a washing fluid, but a dynamic ecosystem and liquid biomarker that reflects and mediates oral dysbiosis. Its composition during the 1000 days establishes lifelong systemic inflammatory

patterns. Early salivary monitoring enables precise interventions that could reduce chronic diseases by 20-35%.

## 5.1 Implications for Clinical Practice



1. Universal prenatal screening of maternal salivary CRP could identify 30% of high-risk pregnancies for neonatal dysbiosis.

2. Infant salivary profiling at 12 months predicts caries with AUC 0.85, enabling targeted interventions.

3. Salivary biomarkers (gingipainases, miR-203) could replace invasive markers in cardiovascular risk monitoring.

#### 5.2 Future Research Directions

1. Develop salivary point-of-care devices for real-time pH, buffer and protease measurement.

2. Validate salivary microbial signature as predictor of response to cancer immunotherapy.

3. Explore saliva transplantation (fecal microbiota transplantation-style) to restore oral homeostasis.

#### 6. LIMITATIONS

1. Methodological heterogeneity: Variability in salivary collection techniques (stimulated vs. unstimulated) limits comparability.

2. Causality: Most evidence is observational; randomized controlled trials of early salivary interventions are scarce.

3. Studied populations: Predominance of Caucasian cohorts; validation in diverse populations is needed.

#### 7. DECLARATIONS

**Ethics:** No approval required as systematic review.

**Conflicts of Interest:** The author declares no conflicts.

**Funding:** This work received no specific funding.

**Author Contribution:** A.R. conceptualized, wrote and reviewed the entire manuscript.

**Acknowledgments:** To researchers whose work underpins this synthesis.



## 8. REFERENCES

1. Chimenos Küstner E, López-López J. La saliva: ecosistema y biomarcador en la disbiosis oral / Saliva: ecosystem and biomarker in oral dysbiosis. *Med Oral Patol Oral Cir Bucal*. 2024;29(1):e1-e10. doi:10.4317/medoral.26045
2. Willis JR, Gabaldón T. The human oral microbiome in health and disease: from sequences to ecosystems. *Microorganisms*. 2020;8(2):308. doi:10.3390/microorganisms8020308
3. Sampedro MF, Arce RM. Early-life oral microbiota colonization: the gateway to systemic health / Colonización temprana de microbiota oral: la puerta a la salud sistémica. *J Dent Res*. 2023;102(3):245-252. doi:10.1177/00220345221133275
4. Gao L, Xu T, Huang G, et al. Oral microbiomes: more and more evidence in oral cavity diseases / Microbiomas orales: cada vez más evidencia en enfermedades de la cavidad oral. *Int J Oral Sci*. 2021;13(1):49. doi:10.1038/s41368-021-00159-9
5. Dzidic M, Boix-Amoros A, Selma-Royo M, et al. Gut microbiota and mucosal immunity in the neonate / Microbiota intestinal e inmunidad mucosa en el neonato. *Med Sci (Basel)*. 2018;6(3):56. doi:10.3390/medsci6030056
6. Figuero E, Han YW, Furuichi Y. Periodontal diseases and adverse pregnancy outcomes: mechanisms / Enfermedades periodontales y resultados adversos del embarazo: mecanismos. *Periodontol 2000*. 2021;87(1):195-215. doi:10.1111/prd.12395
7. Corbella S, Taschieri S, Del Fabbro M, et al. Adverse pregnancy outcomes and periodontitis: a systematic review and meta-analysis exploring potential association / Resultados adversos del embarazo y periodontitis: revisión sistemática y metaanálisis explorando asociación potencial. *Quintessence Int*. 2016;47(3):193-204. doi:10.3290/j.qi.a35027

8. Lif Holgerson P, Harnevik L, Hernell O, et al. Mode of birth delivery affects oral microbiota in infants / El modo de parto afecta la microbiota oral en lactantes. J Dent Res. 2011;90(10):1183-1188. doi:10.1177/0022034511418973
9. Rutayisire E, Huang K, Liu Y, et al. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants' life: a systematic review / El modo de parto afecta la diversidad y patrón de colonización de la microbiota intestinal durante el primer año de vida del lactante: revisión sistemática. BMC Gastroenterol. 2016;16:86. doi:10.1186/s12876-016-0498-0
10. Holgerson PL, Vestman NR, Claesson R, et al. Oral microbial profile discriminates breast-fed from formula-fed infants / El perfil microbiano oral discrimina lactantes amamantados de los alimentados con fórmula. J Pediatr Gastroenterol Nutr. 2013;56(2):127-136. doi:10.1097/MPG.0b013e31826f2b85
11. Diaz PI, Hong BY, Dupuy AK, et al. Microbiome networks during early colonization of the oral cavity / Redes del microbioma durante la colonización temprana de la cavidad oral. ISME J. 2017;11(12):2850-2863. doi:10.1038/ismej.2017.152
12. Sanz M, D'Aiuto F, Deanfield J, et al. European workshop in periodontology / Taller europeo de periodontología. J Clin Periodontol. 2020;47(Suppl 21):4-6. doi:10.1111/jcpe.13225
13. Pitts NB, Zero DT, Marsh PD, et al. Dental caries / Caries dental. Nat Rev Dis Primers. 2017;3:17030. doi:10.1038/nrdp.2017.30
14. Burton JP, Chilcott CN, Moore CJ, et al. A preliminary study of the effect of probiotic *Streptococcus salivarius* K12 on oral malodour parameters / Estudio preliminar del efecto del probiótico *Streptococcus salivarius* K12 en parámetros de mal olor oral. J Appl Microbiol. 2006;100(4):754-764. doi:10.1111/j.1365-2672.2006.02823.x

15. Manoharan S, Patel B, Kamer AR, et al. Salivary biomarkers of oral and systemic diseases / Biomarcadores salivales de enfermedades orales y sistémicas. Adv Clin Chem. 2020;96:1-47. doi:10.1016/bs.acc.2020.03.001
16. Peres KG, Cascaes AM, Peres MA, et al. Exclusive breastfeeding and risk of dental malocclusions / Lactancia materna exclusiva y riesgo de maloclusiones dentales. Pediatrics. 2015;136(1):e60-e67. doi:10.1542/peds.2014-3276
17. Leira Y, Seoane J, Blanco M, et al. Association between periodontitis and ischemic stroke: a systematic review and meta-analysis / Asociación entre periodontitis y accidente cerebrovascular isquémico: revisión sistemática y metaanálisis. Eur J Epidemiol. 2017;32(1):43-53. doi:10.1007/s10654-016-0200-4
18. Krom BP, Buijs MJ, Ten Cate JM, et al. Oral microbiome and cancer: epidemiological, clinical and molecular evidence / Microbioma oral y cáncer: evidencia epidemiológica, clínica y molecular. Crit Rev Microbiol. 2020;46(5):547-564. doi:10.1080/1040841X.2020.1810392
19. Ogata Y, Takahashi Y, Atarashi R, et al. Salivary microRNA expression profiling in periodontitis: a pilot study / Perfil de expresión de microRNA salival en periodontitis: estudio piloto. J Periodontal Res. 2019;54(3):260-267. doi:10.1111/jre.12629
20. Thomson WM. Dry mouth and older people / Boca seca y personas mayores. Aust Dent J. 2015;60 Suppl 1:54-63. doi:10.1111/adj.12264
21. Quagliarello V, Ginter S, Han L, et al. Modifiable risk factors for nursing home-acquired pneumonia / Factores de riesgo modificables para neumonía adquirida en residencias de ancianos. Clin Infect Dis. 2005;40(1):1-6. doi:10.1086/426023
22. Terpenning MS, Taylor GW, Lopatin DE, et al. Aspiration pneumonia: dental and oral risk factors in an older veteran population /

Neumonía aspirativa: factores de riesgo dental y oral en una población de veteranos mayores. J Am Geriatr Soc. 2001;49(5):557-563.  
doi:10.1046/j.1532-5415.2001.49113.x

23. Hajishengallis G. The inflammophilic character of the periodontitis-associated microbiota / El carácter inflamófilo de la microbiota asociada a periodontitis. Mol Oral Microbiol. 2014;29(6):248-257.  
doi:10.1111/omi.12065

24. Dorn BR, Dunn WA Jr, Progulski-Fox A. Invasion of human coronary artery cells by periodontal pathogens / Invasión de células de arteria coronaria humana por patógenos periodontales. Infect Immun. 1999;67(11):5792-5798. doi:10.1128/IAI.67.11.5792-5798.1999

25. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis / Revisión sistemática y metaanálisis de proteína C reactiva en relación con periodontitis. J Clin

Periodontol. 2008;35(4):277-290.  
doi:10.1111/j.1600-051X.2008.01229.x

26. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance / Expresión de factor de necrosis tumoral-a en tejido adiposo: rol directo en resistencia a insulina ligada a obesidad. Science. 1993;259(5091):87-91.  
doi:10.1126/science.7678183

27. Moffatt CE, Lamont RJ. Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells / Inducción de expresión de microRNA-203 por Porphyromonas gingivalis controla supresor de señalización de citocinas 3 en células epiteliales gingivales. Infect Immun. 2011;79(7):2632-2637. doi:10.1128/IAI.00088-11

28. Cai L, Zhu H, Mou Q, et al. Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and

epigenetic aberrations in oral cavity squamous  
cell carcinoma / Análisis integrativo revela  
asociaciones entre disbiosis de microbiota oral y  
aberraciones genéticas y epigenéticas del  
huésped en carcinoma de células escamosas de  
cavidad oral. NPJ Biofilms Microbiomes.  
2024;10:55. doi:10.1038/s41522-024-00511-x